挺进美女教师的蜜桃肥臀视频-同性恋一级片-同性情a三级a三级a三级-同性做爰猛烈全过程-91丨porny丨国产麻豆-91丨porny丨国产入口

澳大利亞Bionomics  
是一個生產的藥物發現和開發新的治療癌癥和嚴重的疾病，中樞神經系統（CNS）通過應用其專有技術平臺MultiCore?, Angene? and ionX?, 多個候選藥物和癌癥，焦慮癥，多發性硬化癥和癲癇治療領域的目標。

Bionomics is a productive drug discovery and development engine room focused on new treatments for cancer and serious disorders of the central nervous system (CNS). Through application of its proprietary technology platforms, MultiCore?, Angene? and ionX?, Bionomics has generated multiple drug candidates and targets in the therapeutic areas of Cancer, Anxiety, Multiple Sclerosis and Epilepsy. The company has a strong out-license record in conjunction with its in-house development program which has seen two highly promising drugs enter clinical trials in the past two years.

Background

Bionomics was founded in 1999 by a group of Australia's leading healthcare researchers and initially established technology platforms in the genomics of epilepsy, angiogenesis and breast cancer.

Using its CNS technologies, Bionomics became the first company in the world to develop a genetic test for Severe Myoclonic Epilepsy of Infants, a "catastrophic" form of epilepsy for which standard treatments are inappropriate.

Using its Angene? cancer target discovery platform, Bionomics has identified over 150 human genes implicated in angiogenesis - the growth in blood vessels that feed tumours.

In 2005, the company achieved significant milestones in applying its technology to drug discovery. Through the acquisition of two companies, Neurofit Preclinical Research and Iliad Chemicals, it became the first company in Australia to establish a fully-integrated small molecule drug discovery platform. The company now has proprietary technologies for each step in the drug discovery process: Target Discovery and Validation, Compound Libraries, High Throughput Screening, Medicinal Chemistry and Preclinical Development.

The company has internal small molecule discovery programs operating in the following four areas: Angiogenesis and Vascular Targeting Agents (Cancer); Anxiety/Epilepsy and Multiple Sclerosis (CNS diseases).

Bionomics has commercial partnerships with a number of leading healthcare companies including Merck Serono, GenMab, Athena Diagnostics, LabCorp, Perkin Elmer, and Genetic Technologies Ltd.